[go: up one dir, main page]

Emanuelli et al., 2017 - Google Patents

Smurf2-mediated stabilization of DNA topoisomerase IIα controls genomic integrity

Emanuelli et al., 2017

View PDF
Document ID
2399617922703779556
Author
Emanuelli A
Borroni A
Apel-Sarid L
Shah P
Ayyathan D
Koganti P
Levy-Cohen G
Blank M
Publication year
Publication venue
Cancer Research

External Links

Snippet

DNA topoisomerase IIα (Topo IIα) ensures genomic integrity and unaltered chromosome inheritance and serves as a major target of several anticancer drugs. Topo IIα function is well understood, but how its expression is regulated remains unclear. Here, we identify the …
Continue reading at www.researchgate.net (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electro-chemical, or magnetic means
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids

Similar Documents

Publication Publication Date Title
Emanuelli et al. Smurf2-mediated stabilization of DNA topoisomerase IIα controls genomic integrity
Ji et al. TRIM22 activates NF-κB signaling in glioblastoma by accelerating the degradation of IκBα
Yang et al. The deubiquitinase USP38 promotes NHEJ repair through regulation of HDAC1 activity and regulates cancer cell response to genotoxic insults
Her et al. Potent effect of the MDM2 inhibitor AMG232 on suppression of glioblastoma stem cells
Messick et al. The ubiquitin landscape at DNA double-strand breaks
Chen et al. Wnt‐induced deubiquitination FoxM1 ensures nucleus β‐catenin transactivation
Nishikawa et al. BRCA1-associated protein 1 interferes with BRCA1/BARD1 RING heterodimer activity
Baumann et al. Disruption of the PRKCD–FBXO25–HAX-1 axis attenuates the apoptotic response and drives lymphomagenesis
Wang et al. PTEN regulates RPA1 and protects DNA replication forks
Adon et al. Cdk2 and Cdk4 regulate the centrosome cycle and are critical mediators of centrosome amplification in p53-null cells
Kim et al. CIP2A modulates cell-cycle progression in human cancer cells by regulating the stability and activity of Plk1
Picco et al. Novel WRN helicase inhibitors selectively target microsatellite-unstable cancer cells
Martínez-Carreres et al. CDK4 regulates lysosomal function and mTORC1 activation to promote cancer cell survival
Kim et al. Regulating BRCA1 protein stability by cathepsin S-mediated ubiquitin degradation
Cheresh et al. Asbestos-induced pulmonary fibrosis is augmented in 8-oxoguanine DNA glycosylase knockout mice
US20180073039A1 (en) Homologous recombination factors
Seo et al. Syntaphilin ubiquitination regulates mitochondrial dynamics and tumor cell movements
Xu et al. MEN1 degradation induced by Neddylation and the CUL4B–DCAF7 axis promotes pancreatic neuroendocrine tumor progression
Kim et al. Stratifin regulates stabilization of receptor tyrosine kinases via interaction with ubiquitin-specific protease 8 in lung adenocarcinoma
Choi et al. Programmed cell death 5 mediates HDAC3 decay to promote genotoxic stress response
Schleich et al. H3K9me3-mediated epigenetic regulation of senescence in mice predicts outcome of lymphoma patients
Kim et al. Mutant GTF2I induces cell transformation and metabolic alterations in thymic epithelial cells
Lukinović et al. Smyd3 impedes small cell lung cancer sensitivity to alkylation damage through rnf113a methylation–phosphorylation cross-talk
Osei-Amponsa et al. Impact of losing hRpn13 Pru or UCHL5 on proteasome clearance of ubiquitinated proteins and RA190 cytotoxicity
Bei et al. Passenger gene coamplifications create collateral therapeutic vulnerabilities in cancer